N-Nitrosodimethylamine Contamination in the Metformin Finished Products

A GC–MS/MS method with EI ionization was developed and validated to detect and quantify N-nitrosodimethylamine (NDMA) and seven other nitrosamines in 105 samples of metformin tablets from 13 different manufactures. Good linearity for each compound was demonstrated over the calibration range of 0.5–9...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecules (Basel, Switzerland) Jg. 25; H. 22; S. 5304
Hauptverfasser: Zmysłowski, Adam, Książek, Iza, Szterk, Arkadiusz
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI 13.11.2020
MDPI AG
Schlagworte:
Calibration
Dimethylnitrosamine - chemistry
Drug Contamination
Drug Design
Europe
Gas Chromatography-Mass Spectrometry
GC-MS
Limit of Detection
Linear Models
metformin
Metformin - analysis
Metformin - chemistry
NDMA
nitrosamines
Pharmaceutical Preparations - analysis
Powders
Solvents
Tablets
Tandem Mass Spectrometry
Temperature
Europe
GC-MS
metformin
nitrosamines
NDMA
ISSN:1420-3049, 1420-3049
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A GC–MS/MS method with EI ionization was developed and validated to detect and quantify N-nitrosodimethylamine (NDMA) and seven other nitrosamines in 105 samples of metformin tablets from 13 different manufactures. Good linearity for each compound was demonstrated over the calibration range of 0.5–9.5 ng/mL. The assay for all substances was accurate and precise. NDMA was not detected in the acquired active pharmaceutical ingredient (API); however, NDMA was detected in 64 (85.3%) and 22 (91.7%) of the finished product and prolonged finished product samples, respectively. European Medicines Agency recommends the maximum allowed limit of 0.032 ppm in the metformin products. Hence, 28 finished products and 7 pronged dosage products were found to exceed the acceptable limit of daily intake of NDMA contamination. The implications of our findings for the testing of pharmaceutical products are discussed.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules25225304